Endocrine journal最新文献

筛选
英文 中文
Mutual associations among responsiveness to differential diagnostic tests for Cushing's disease, tumor size, and somatostatin receptor 5 expression in corticotroph tumors. 皮质营养肿瘤中对库欣病鉴别诊断测试的反应性、肿瘤大小和体生长抑素受体 5 表达之间的相互关联。
IF 1.3 4区 医学
Endocrine journal Pub Date : 2025-01-06 Epub Date: 2024-10-24 DOI: 10.1507/endocrj.EJ24-0344
Karolina Budzen, Kosuke Mukai, Yuto Mitsui, Michio Otsuki, Atsunori Fukuhara, Satoru Oshino, Youichi Saitoh, Masaharu Kohara, Eiichi Morii, Iichiro Shimomura
{"title":"Mutual associations among responsiveness to differential diagnostic tests for Cushing's disease, tumor size, and somatostatin receptor 5 expression in corticotroph tumors.","authors":"Karolina Budzen, Kosuke Mukai, Yuto Mitsui, Michio Otsuki, Atsunori Fukuhara, Satoru Oshino, Youichi Saitoh, Masaharu Kohara, Eiichi Morii, Iichiro Shimomura","doi":"10.1507/endocrj.EJ24-0344","DOIUrl":"10.1507/endocrj.EJ24-0344","url":null,"abstract":"<p><p>There are differences in the responsiveness to differential diagnostic tests for Cushing's disease (CD), corticotroph tumor size, and the somatostatin receptor (SSTR) 5 expression in corticotroph tumors between CD patients. The differences in SSTR5 expression are particularly significant for identifying therapeutic targets for CD. However, prospective predictors of SSTR5 expression remain unclear. Thus, our objective was to elucidate the relationships among these clinical characteristics of CD, including SSTR5 expression. In 27 hospitalized patients with CD at Osaka University Hospital, Osaka, Japan, associations between corticotroph tumor diameter, the response of ACTH and cortisol to differential diagnostic tests for CD (CRH, desmopressin [DDAVP], and high-dose dexamethasone suppression test [HDDST]), the ACTH/cortisol index, and the SSTR5 immunoreactive score were retrospectively investigated. The response to differential diagnostic tests, ACTH/cortisol index, tumor diameter, and SSTR5 expression were significantly related (vs. tumor diameter [CRH: r = -0.54; DDAVP: r = -0.54; HDDST r = -0.67; ACTH/cortisol index: r = 0.76; SSTR5: r = -0.61], vs. CRH [DDAVP: r = 0.63, HDDST: r = 0.72, ACTH/cortisol index: r = -0.45; SSTR5: r = 0.56], vs. DDAVP [HDDST: r = 0.66; ACTH/cortisol index: r = -0.46; SSTR5: r = 0.76], vs. HDDST [ACTH/cortisol index: r = -0.62; SSTR5: r = 0.77], ACTH/cortisol index vs. SSTR5: r = -0.67). The areas under the receiver operating characteristic curve for the prediction of high SSTR5 expression via the CRH test, DDAVP test, HDDST, ACTH/cortisol index, and tumor diameter were 0.79, 0.87, 0.80, 0.71, and 0.71, respectively. Tests for differential diagnosis of CD, the ACTH/cortisol index, and the corticotroph tumor diameter have the potential for identifying SSTR5 expression in corticotroph tumors. These parameters may reflect the biological characteristics of corticotroph tumors.</p>","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":"93-102"},"PeriodicalIF":1.3,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11778363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current status of the thyroid hormone measurement items in patients receiving levothyroxine monotherapy by the management based on the thyroid tissue volume. 根据甲状腺组织容积管理接受左甲状腺素单药治疗的患者的甲状腺激素测量项目现状。
IF 1.3 4区 医学
Endocrine journal Pub Date : 2025-01-06 Epub Date: 2024-10-23 DOI: 10.1507/endocrj.EJ24-0259
Mitsuru Ito, Hanna Deguchi-Horiuchi, Sawako Takahashi, Mako Hisakado, Kazuyoshi Kohsaka, Eijun Nishihara, Shuji Fukata, Mitsushige Nishikawa, Akira Miyauchi, Takashi Akamizu
{"title":"Current status of the thyroid hormone measurement items in patients receiving levothyroxine monotherapy by the management based on the thyroid tissue volume.","authors":"Mitsuru Ito, Hanna Deguchi-Horiuchi, Sawako Takahashi, Mako Hisakado, Kazuyoshi Kohsaka, Eijun Nishihara, Shuji Fukata, Mitsushige Nishikawa, Akira Miyauchi, Takashi Akamizu","doi":"10.1507/endocrj.EJ24-0259","DOIUrl":"10.1507/endocrj.EJ24-0259","url":null,"abstract":"<p><p>We and other investigators reported that mild TSH suppression with levothyroxine (LT<sub>4</sub>) was needed to achieve normal free triiodothyronine (FT<sub>3</sub>) levels and metabolic euthyroid state in athyreotic patients. Consequently, management methods based on thyroid tissue volume have been implemented for patients receiving LT<sub>4</sub> at the Kuma Hospital. This retrospective study examined the composition of the thyroid hormone measurement items (serum-free thyroxine [FT<sub>4</sub>], FT<sub>3</sub>, and FT<sub>4</sub> + FT<sub>3</sub>) in patients receiving LT<sub>4</sub> monotherapy. According to the etiology of hypothyroidism, 36% of the 25,523 patients included in this study underwent total thyroidectomy (TT). Thirteen percent and 14% had undergone <sup>131</sup>I treatment for hyperthyroidism (RIT) and partial thyroidectomy (PT), respectively. Moreover, 37% of patients had received non-invasive treatment (NIT). The proportion of patients who underwent only FT<sub>3</sub> measurements was higher (TT, 93%; RIT, 61%) in the first two groups, whereas the proportion of patients who underwent only FT<sub>4</sub> measurements was higher (PT, 50%; NIT, 65%) in the remaining two groups. Only FT<sub>3</sub> measurements were performed in 58% of patients. Only FT<sub>4</sub> measurements were performed in 34% of patients. The serum TSH levels were suppressed in nearly half of the patients (46%). Thus, FT<sub>3</sub> was the major thyroid hormone measured in patients receiving LT<sub>4</sub> treatment, and the serum TSH levels were suppressed in nearly half of the patients. This may be attributed to the management guidelines at our hospital, a specialized facility for thyroid disease, wherein half of the patients present are athyreotic or have atrophic thyroid glands after TT or RIT.</p>","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":"69-77"},"PeriodicalIF":1.3,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11778342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MicroRNA-122 protects against interferon-α-induced hepatic inflammatory response via the Janus kinase-signal transducer and activator of transcription pathway. MicroRNA-122 通过 Janus 激酶-信号转导和转录激活因子通路防止干扰素-α 诱导的肝脏炎症反应。
IF 1.3 4区 医学
Endocrine journal Pub Date : 2025-01-06 Epub Date: 2024-10-01 DOI: 10.1507/endocrj.EJ24-0317
Fanwei Liu, Bowen Liu, Shanshan Xu, Yinhua Ni, Xiaoli Liu
{"title":"MicroRNA-122 protects against interferon-α-induced hepatic inflammatory response via the Janus kinase-signal transducer and activator of transcription pathway.","authors":"Fanwei Liu, Bowen Liu, Shanshan Xu, Yinhua Ni, Xiaoli Liu","doi":"10.1507/endocrj.EJ24-0317","DOIUrl":"10.1507/endocrj.EJ24-0317","url":null,"abstract":"<p><p>Significant overlap in the epidemiology and coinfection of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) has been identified, which accelerates the development of severe liver cirrhosis and hepatocellular carcinoma worldwide. Interferon-α (IFN-α), a cytokine with antiviral properties, exerts profound physiological effects on innate immunity by regulating interferon-stimulated genes (ISGs) within cells. However, the underlying mechanism of IFN-α in hepatic inflammation remains to be fully elucidated. Here, we utilized LO2 cells treated with the recombinant IFN-α protein and conducted microRNA (miR) sequencing. MiR-122-3p and miR-122-5p_R+1 were the most enriched miRNAs involved in the pathogenesis of IFN-α-induced inflammatory responses and were significantly downregulated by IFN-α treatment. Furthermore, we identified interferon induced protein with tetratricopeptide repeats 1 (IFIT1) as a potential target gene of miR-122. IFN-α markedly increased the expression of proinflammatory cytokines and fibrogenic genes but decreased the mRNA expression of ISGs. Additionally, IFN-α significantly activated the NF-κB p-p65, MAPK p-p38, and Jak/STAT pathways to trigger inflammation. Importantly, supplementation with a miR-122 mimic significantly alleviated IFN-α-induced inflammation and induced IFIT1 expression in LO2 cells. Conversely, the suppression of miR-122 markedly exacerbated the inflammatory response triggered by IFN-α. Furthermore, silencing IFIT1 via an siRNA elicited an inflammatory response, whereas IFIT1 overexpression ameliorated hepatic inflammation and fibrosis in a manner comparable to that induced by IFN-α treatment. Taken together, our findings suggest that miR-122 and its target, IFIT1, reciprocally regulate the inflammatory response associated with IFN through the Jak/STAT pathway.</p>","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":"53-67"},"PeriodicalIF":1.3,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11778391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence of the postpartum diagnosis of thyroid eye disease in relation to thyroid function in Graves' disease. 与巴塞杜氏病甲状腺功能有关的产后甲状腺眼病诊断率。
IF 1.3 4区 医学
Endocrine journal Pub Date : 2025-01-06 Epub Date: 2024-10-23 DOI: 10.1507/endocrj.EJ24-0401
Nami Suzuki, Jaeduk Yoshimura Noh, Ai Kozaki, Natsuko Watanabe, Ai Yoshihara, Miho Fukushita, Masako Matsumoto, Hideyuki Imai, Shigenori Hiruma, Masahiro Ichikawa, Masakazu Koshibu, Akiko Sankoda, Rei Hirose, Toshu Inoue, Kiminori Sugino, Koichi Ito
{"title":"Incidence of the postpartum diagnosis of thyroid eye disease in relation to thyroid function in Graves' disease.","authors":"Nami Suzuki, Jaeduk Yoshimura Noh, Ai Kozaki, Natsuko Watanabe, Ai Yoshihara, Miho Fukushita, Masako Matsumoto, Hideyuki Imai, Shigenori Hiruma, Masahiro Ichikawa, Masakazu Koshibu, Akiko Sankoda, Rei Hirose, Toshu Inoue, Kiminori Sugino, Koichi Ito","doi":"10.1507/endocrj.EJ24-0401","DOIUrl":"10.1507/endocrj.EJ24-0401","url":null,"abstract":"<p><p>It has been reported that Graves' disease (GD) sometimes improves spontaneously during pregnancy, although exacerbation of GD during postpartum period or relapse of hyperthyroidism caused by GD might occur. This study aimed to investigate the incidence of postpartum diagnosis of thyroid eye disease (TED) in relation to thyroid dysfunction. This retrospective cross-sectional study enrolled 11,104 deliveries from the patients with GD between January 2004 and August 2022. Within the 12-month postpartum period, 72 patients (0.65%) were diagnosed with TED. The thyroid function of the 72 patients comprised 9 remission, 13 continued antithyroid medicine, and 50 thyroid dysfunction; 30 newly diagnosed GD, 1 hypothyroidism, and 19 relapse/recurrence of GD. In the 49 patients with thyroid dysfunction, no difference was observed in the median values of thyroid-stimulating hormone (TSH) receptor antibody (TRAb) and TSH receptor stimulating antibody between the TED diagnosis and the development of hyperthyroidism. However, when the patients were classified into the newly developed GD and relapse/recurrence of GD groups, the difference became significant and the TRAb level was high in the newly developed GD (16.1 vs. 5.0 IU/L, p < 0.0001, and 15.0 vs. 6.0 IU/L, p = 0.0003). Thyroid dysfunction preceded TED diagnosis in more than half of the patients and the median time for each event was 6.5 vs. 8.1 months. The active phase TED was observed in 8 of the 72 patients. Of the 72 patients newly diagnosed with TED in postpartum, two-thirds were accompanied by thyroid dysfunction and 8 of them were in active phase.</p>","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":"103-113"},"PeriodicalIF":1.3,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11778393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between non-high-density lipoprotein cholesterol and type 2 diabetes: a systematic review and meta-analysis of cohort studies. 非高密度脂蛋白胆固醇与 2 型糖尿病的关系:队列研究的系统回顾和荟萃分析。
IF 1.3 4区 医学
Endocrine journal Pub Date : 2025-01-06 Epub Date: 2024-09-20 DOI: 10.1507/endocrj.EJ24-0189
Mengqi Han, Yue Shen, Xin Guo, Cheng Hong, Xincan Ji, Haoyang Guo, Yuelong Jin, Hui Yuan
{"title":"Association between non-high-density lipoprotein cholesterol and type 2 diabetes: a systematic review and meta-analysis of cohort studies.","authors":"Mengqi Han, Yue Shen, Xin Guo, Cheng Hong, Xincan Ji, Haoyang Guo, Yuelong Jin, Hui Yuan","doi":"10.1507/endocrj.EJ24-0189","DOIUrl":"10.1507/endocrj.EJ24-0189","url":null,"abstract":"<p><p>Non-high-density lipoprotein cholesterol (non-HDL), a more readily available and reliable lipid parameter, is unclear in its association with type 2 diabetes (T2D). Previous studies assessing the relationship between non-HDL and T2D risk remains inconsistent results. We performed a meta-analysis to systematically evaluate this association. The PubMed, EMBASE, Medline, Web of Science, and Cochrane Library databases were systematically searched to find articles on \"non-HDL\" and \"T2D\" from inception to December 6, 2023. A random-effects model was used to calculate the effect estimates and 95% confidence intervals. Subgroup analyses and univariate Meta-regression were performed to explore sources of heterogeneity. The main exposure and outcome were non-HDL and T2D, respectively, in the general population. A total of 8 studies included 251,672 participants who met the inclusion criteria for this study. Meta-analysis showed that higher non-HDL increased the risk of T2D compared with the lower non-HDL group (total effect size: 1.16; 95% CI 1.079-1.251, p < 0.001). Subgroup analyses and Meta-regression of the association between non-HDL and T2D were not affected by region, proportion of men, sample size, or adjustment for confounders (including BMI, hypertension, waist circumference, and family history of diabetes). Higher non-HDL may be associated with an increased risk of T2D. Large prospective cohort studies are needed to validate these findings, and further studies are required in order to elucidate the underlying pathophysiologic mechanisms underlying the association between non-HDL and T2D.</p>","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":"43-51"},"PeriodicalIF":1.3,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11778345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibition of mmu_circ_0009303 improves metabolic dysfunction-associated steatotic liver disease by regulating lipid metabolism and oxidative stress. 通过调节脂质代谢和氧化应激,抑制 mmu_circ_0009303 可改善代谢功能障碍相关的脂肪性肝病。
IF 1.3 4区 医学
Endocrine journal Pub Date : 2025-01-06 Epub Date: 2024-10-24 DOI: 10.1507/endocrj.EJ24-0008
Ju Zhou, Wu Li, Xiaowei Chi, Dingchun Li, Chunxia Yang, Zhiwen Duan
{"title":"Inhibition of mmu_circ_0009303 improves metabolic dysfunction-associated steatotic liver disease by regulating lipid metabolism and oxidative stress.","authors":"Ju Zhou, Wu Li, Xiaowei Chi, Dingchun Li, Chunxia Yang, Zhiwen Duan","doi":"10.1507/endocrj.EJ24-0008","DOIUrl":"10.1507/endocrj.EJ24-0008","url":null,"abstract":"<p><p>Circular RNAs (circRNAs) play an important role in regulating inflammation and oxidative stress during the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD); however, the underlying mechanism is unclear. This study aimed to determine the role of mmu_circ_0009303 in MASLD. We used a bioinformatics approach to identify potential targets and established an in vitro model of MASLD. Oil red O staining, cell transfection and dual-luciferase reporter assay were used to determine the role of mmu_circ_0009303. The results indicated that the mmu_circ_0009303 expression was significantly increased in the MASLD model both in vitro and in vivo and was associated with oxidative stress levels and inflammation. Moreover, bioinformatics analyses revealed that miRNA-182-5p and Foxo3 are targets of mmu_circ_0009303 and miRNA-182-5p, respectively. In the in vitro MASLD model, mmu_circ_0009303 promoted fat deposition in NCTC1469 cells, which was induced by free fatty acid (FFA) through the regulation of miRNA-182-5p/Foxo3. The expression of miRNA-182-5p and Forkhead box O3 (Foxo3) was associated with mmu_circ_0009303 expression in the liver of mice with MASLD, which was induced by a high-fat diet. Furthermore, mmu_circ_0009303 may be involved in regulating the expression of lipid metabolism-related regulatory proteins, such as CPT1A, SLC27A4, ACBD3, SREBP1, FAS, PPARα, and PPARγ. Taken together, mmu_circ_0009303 promotes oxidative stress, inflammation, and excessive fat accumulation in NCTC1469 cells induced by FFA through the regulation of miRNA-182-5p/Foxo3 and lipid metabolism-related regulatory proteins. These findings provide a potential target for the treatment of MASLD.</p>","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":"79-91"},"PeriodicalIF":1.3,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11778371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Celebrating the 100th anniversary of the Japan Endocrine Society: reflecting on my 50 years of hormone research. 庆祝日本内分泌学会成立100周年:反思我50年的激素研究。
IF 1.3 4区 医学
Endocrine journal Pub Date : 2025-01-01 DOI: 10.1507/endocrj.EJ20241105
Kazuwa Nakao
{"title":"Celebrating the 100<sup>th</sup> anniversary of the Japan Endocrine Society: reflecting on my 50 years of hormone research.","authors":"Kazuwa Nakao","doi":"10.1507/endocrj.EJ20241105","DOIUrl":"10.1507/endocrj.EJ20241105","url":null,"abstract":"","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":"72 1","pages":"1-21"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Three distinctive activities of the Gender Equality Promotion Committee (JES We Can). 性别平等促进委员会(JES We Can)的三项特色活动。
IF 1.3 4区 医学
Endocrine journal Pub Date : 2025-01-01 DOI: 10.1507/endocrj.EJ20241024
Mayumi Yamamoto
{"title":"Three distinctive activities of the Gender Equality Promotion Committee (JES We Can).","authors":"Mayumi Yamamoto","doi":"10.1507/endocrj.EJ20241024","DOIUrl":"10.1507/endocrj.EJ20241024","url":null,"abstract":"","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":"72 3","pages":"239-242"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A 40-year challenge to resolve clinical questions through experimental/laboratory techniques. 通过实验/实验室技术解决临床问题的40年挑战。
IF 1.3 4区 医学
Endocrine journal Pub Date : 2025-01-01 DOI: 10.1507/endocrj.EJ20250116
Yasumasa Iwasaki
{"title":"A 40-year challenge to resolve clinical questions through experimental/laboratory techniques.","authors":"Yasumasa Iwasaki","doi":"10.1507/endocrj.EJ20250116","DOIUrl":"https://doi.org/10.1507/endocrj.EJ20250116","url":null,"abstract":"","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":"72 5","pages":"447-456"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In celebration of 100 exciting years of the Japan Endocrine Society. 为了庆祝日本内分泌学会成立100周年。
IF 1.3 4区 医学
Endocrine journal Pub Date : 2025-01-01 DOI: 10.1507/endocrj.EJ20241021
Mari Suzuki Hotta
{"title":"In celebration of 100 exciting years of the Japan Endocrine Society.","authors":"Mari Suzuki Hotta","doi":"10.1507/endocrj.EJ20241021","DOIUrl":"10.1507/endocrj.EJ20241021","url":null,"abstract":"","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":"72 2","pages":"123-130"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信